Abstract
There are many benefits of implementing closed, GMP-compliant, digitally connected solutions at earlier stages in CAR T cell therapy development. In this article, we give an overview of one such modular system, followed by a panel discussion with cell therapy industry experts on overcoming bottlenecks in CAR T cell manufacturing with automated solutions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
